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Amiodarone and diffuse alveolar hemorrhage
To the Editor,
Amiodarone, a common anti-arrhythmic 
drug, is well known for its pulmonary toxicity. 
Pulmonary toxicity is reported to occur at a rate 
of 1–5%, with this rate rising with an increased 
daily dose >200mg and drug accumulation over 
several years. Pulmonary toxicity by amiodarone 
may present just few days up to several years after 
the initiation of the drug [1]. Most common com-
plications are chronic interstitial pneumonitis, 
organizing pneumonia, eosinophilic pneumonia, 
pleural effusion, acute respiratory distress syn-
drome (ARDS) and pulmonary nodules/masses 
[2]. Diffuse alveolar hemorrhage (DAH) is de-
scribed as a rare amiodarone-related toxicity, so 
far reported in the form of scarce, very few case 
reports. We report 2 cases of amiodarone-associa-
ted DAH in order to highlight the significance of 
this complication.
Our first case was a 70-year-old female who 
was receiving amiodarone 200 mg per day due 
to supra-ventricular arrhythmias for the past 
5 months. She was asymptomatic, but resting 
hypoxemia was noticed by her cardiologist on 
a regular follow-up visit, along with a new finding 
of pulmonary hypertension of 65 mm Hg. She had 
no evidence of heart failure; a high-resolution 
computed tomography scan (HRCT) then perfor-
med revealed ground-glass opacities distributed 
bilaterally in the upper and lower lung fields, 
along with mosaic attenuation (Figures 1A, 1B). 
Blood tests showed a decrease in hemoglobin le-
vels by 1 g/dL. In bronchoalveolar lavage (BAL), 
58% of alveolar macrophages were hemosiderin-
-laden, positive on Perls’ stain. Autoimmunity
testing and urine sediment were all negative. The
patient responded well to 32 mg prednisone as 
a starting dose. Opacities cleared after 3 months 
of treatment and pulmonary hypertension com-
pletely subsided. 
The second case was a 54-year-old male. 
He received amiodarone for the past 3 weeks at 
a dose of 600 mg per day to control atrial fibril-
lation. He complained of shortness of breath for 
the past 2 days and mild hemoptysis. Cardiac 
function was normal. HRCT scan showed hazy 
opacities bilaterally, ground-glass attenuation 
and increased interstitial markings extending 
at the lung periphery (Figures 1C, 1D). Hemo-
globin was stable and oxygenation normal. BAL 
was macroscopically hemorrhagic and showed 
100% hemosiderin-laden macrophages positive 
on Perls’ stain. He had no evidence of vasculitis 
or hematouria. Apart from amiodarone, he was 
receiving apixaban for the past 6 years; however, 
the latest implemented drug (amiodarone) was 
considered responsible for DAH in this patient. 
He was started on methyl-prednisolone 600 mg/ 
/day for 5 days and then switched to prednisone 
48 mg/day with good response.
Only seven cases of DAH due to amiodarone 
are reported in the literature [3–5]. In one case, 
diagnosis was established post-mortem, while the 
others responded to treatment with corticostero-
ids and removal of amiodarone. Reinstitution of 
amiodarone resulted in repeated DAH incidents. 
Pathogenetically, amiodarone is shown in vitro 
and in vivo studies responsible for interstitial 
pneumonitis by direct cellular cytotoxicity, ac-
cumulation of phospholipid complexes and acti-
vation of angiotensin converting enzyme leading 
to alveolar epithelial and macrophage cells injury 
and apoptosis; indirectly via an immunological 
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Figure 1. A, B. First case of female patient, ground glass and mosaic attenuation bilaterally; C, D. Second case of male patient, hazy ground-glass 
opacities located centrally bilaterally along with interstitial markings at the periphery
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reaction characterized by CD8-T lymphocytosis 
that resembles hypersensitivity pneumonitis [6, 
7]. In the case of amiodarone causing DAH, the 
underlying mechanism responsible is diffuse 
alveolar damage (DAD) [8]. DAD pathology asso-
ciates either with ARDS or with DAH and is cha-
racterized by alveolar septa edema and hyaline 
membranes formation.
DAH in a patient receiving amiodarone who 
presents with symptoms or new radiology findin-
gs has to be differentiated from cardiogenic dise-
ases and from the rest of amiodarone pulmonary 
toxicities. This is based on radiology and pulmo-
nary function tests. Pulmonary function tests in 
DAH will not exhibit significant restriction, while 
diffusing capacity instead of decreased is found 
normal or increased. HRCT is characterized by 
ground-glass attenuation and mosaic pattern in 
adjacent normal lung tissue [9]. Diagnosis is es-
tablished by BAL, which typically demonstrates 
hemosiderin-laden macrophages > 20% of total 
macrophages on Perls’ Prussian Blue stain [10]. 
Lung biopsy is not required for the diagnosis of 
DAH. Both cases cases we present in this study 
had typical HRCT and BAL features.
Treatment strategies for amiodarone inter-
stitial pneumonitis or DAH are based solely on 
case series. While for the former, drug removal 
and/or prednisone 0.5 mg/kg are proposed, it is 
possible that for the latter, pulse corticosteroids 
are required, as in other DAH etiologies. 
In conclusion, as illustrated in our study, 
DAH due to amiodarone may not be as rare as it 
is believed. Since HRCT is not diagnostic, BAL 
should be performed to differentiate from other 
amiodarone-related or other disorders. Awareness 
is mandatory to quickly remove amiodarone and 
initiate corticosteroids.  
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